Securities

December 2023 provided, if nothing else, a ray of hope for those investors that have stuck around for the duration...

November 2023 had cannabis investors saying, “Well, at least it didn’t tank again”. In fact, they were treated to returns...

October 2023 saw precious little support for cannabis equities (see above), and many CRBs returned to their pre-HHS rescheduling announcement...

The CRB Monitor Securities Research team covers all aspects of the publicly-traded cannabis ecosystem, including the regulatory environment, operational expansion/M&A...

With the hysteria over The announcement that the US Department of Health and Human Services recommended rescheduling cannabis to Schedule...

This month we take a closer look at the near-term health of the largest 20 pure play Tier 1 CRBs,...